(Q35038955)

5 August 2017

1 reference

title

Monoclonal antibody therapy for B-cell lymphoma (English)

1 reference

5 August 2017

1 reference

Antonio J Grillo-López

series ordinal

1

1 reference

5 August 2017

publication date

1 December 2002

1 reference

International Journal of Hematology

5 August 2017

published in

1 reference

5 August 2017

volume

76

1 reference

5 August 2017

issue

5

1 reference

5 August 2017

page(s)

385-393

1 reference

https://scigraph.springernature.com/pub.10.1007/bf02982803

5 August 2017

exact match

0 references

cites work

Targeted anti-cancer therapy using rituximab, a chimaeric anti-CD20 antibody (IDEC-C2B8) in the treatment of non-Hodgkin's B-cell lymphoma

1 reference

Crossref

https://api.crossref.org/works/10.1007%2FBF02982803

Phase I clinical trial using escalating single-dose infusion of chimeric anti-CD20 monoclonal antibody (IDEC-C2B8) in patients with recurrent B-cell lymphoma

21 January 2018

1 reference

12 December 2020

A phase I toxicity, pharmacology, and dosimetry trial of monoclonal antibody OKB7 in patients with non-Hodgkin's lymphoma: effects of tumor burden and antigen expression

1 reference

12 December 2020

Report of an international workshop to standardize response criteria for non-Hodgkin's lymphomas. NCI Sponsored International Working Group

1 reference

12 December 2020

Comparison of a standard regimen (CHOP) with three intensive chemotherapy regimens for advanced non-Hodgkin's lymphoma

1 reference

12 December 2020

Phase II study of rituximab in combination with chop chemotherapy in patients with previously untreated, aggressive non-Hodgkin's lymphoma

1 reference

12 December 2020

Rituximab: the first monoclonal antibody approved for the treatment of lymphoma

1 reference

12 December 2020

Rituximab monoclonal antibody as initial systemic therapy for patients with low-grade non-Hodgkin lymphoma

1 reference

12 December 2020

Rituximab: an insider's historical perspective.

1 reference

12 December 2020

Antibodies as cytotoxic therapy

1 reference

12 December 2020

Extended Rituximab (anti-CD20 monoclonal antibody) therapy for relapsed or refractory low-grade or follicular non-Hodgkin's lymphoma

1 reference

12 December 2020

Serotherapy of a patient with a monoclonal antibody directed against a human lymphoma-associated antigen

1 reference

12 December 2020

Radioimmunotherapy of B-cell NHL.

1 reference

12 December 2020

Overview of the clinical development of rituximab: first monoclonal antibody approved for the treatment of lymphoma

1 reference

12 December 2020

Combination immunotherapy of relapsed or refractory low-grade or follicular non-Hodgkin's lymphoma with rituximab and interferon-alpha-2a

1 reference

12 December 2020

Association of serum Rituximab (IDEC-C2B8) concentration and anti-tumor response in the treatment of recurrent low-grade or follicular non-Hodgkin's lymphoma

1 reference

12 December 2020

Treatment of patients with low-grade B-cell lymphoma with the combination of chimeric anti-CD20 monoclonal antibody and CHOP chemotherapy

1 reference

12 December 2020

Response criteria for NHL: importance of 'normal' lymph node size and correlations with response rates

1 reference

12 December 2020

Initial experience with treatment of human B cell lymphoma with anti-CD19 monoclonal antibody

1 reference

12 December 2020

Toxicity and response criteria of the Eastern Cooperative Oncology Group

1 reference

12 December 2020

Monoclonal antibody 1F5 (anti-CD20) serotherapy of human B cell lymphomas

1 reference

12 December 2020

IDEC-C2B8 (Rituximab) anti-CD20 monoclonal antibody therapy in patients with relapsed low-grade non-Hodgkin's lymphoma

1 reference

12 December 2020

Treatment of B-Cell Lymphoma with Monoclonal Anti-Idiotype Antibody

1 reference

12 December 2020

CAMPATH-1H monoclonal antibody in therapy for previously treated low-grade non-Hodgkin's lymphomas: a phase II multicenter study. European Study Group of CAMPATH-1H Treatment in Low-Grade Non-Hodgkin's Lymphoma

1 reference

12 December 2020

Pivotal study of iodine I 131 tositumomab for chemotherapy-refractory low-grade or transformed low-grade B-cell non-Hodgkin's lymphomas.

1 reference

12 December 2020

Single-agent monoclonal antibody efficacy in bulky non-Hodgkin's lymphoma: results of a phase II trial of rituximab

1 reference

12 December 2020

Safety of fludarabine, mitoxantrone, and dexamethasone combined with rituximab in the treatment of stage IV indolent lymphoma

1 reference

12 December 2020

Continuous cultures of fused cells secreting antibody of predefined specificity

1 reference

12 December 2020

CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma

1 reference

12 December 2020

Rituximab (anti-CD20 monoclonal antibody) as single first-line therapy for patients with follicular lymphoma with a low tumor burden: clinical and molecular evaluation

1 reference

12 December 2020

Toxin-labeled monoclonal antibodies

1 reference

12 December 2020

Rituximab chimeric anti-CD20 monoclonal antibody therapy for relapsed indolent lymphoma: half of patients respond to a four-dose treatment program.

1 reference

12 December 2020

Identifiers

DOI

10.1007/BF02982803

1 reference

5 August 2017

1 reference